Breaking News Instant updates and real-time market news.

AVXS

AveXis

$47.51

2.35 (5.20%)

08:25
10/10/16
10/10
08:25
10/10/16
08:25

AveXis to host conference call

Conference call to discuss the AVXS-101 clinical update will be held on October 10 at 8:30 am. Webcast Link

  • 10

    Oct

  • 06

    Nov

AVXS AveXis
$47.51

2.35 (5.20%)

09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
10/06/16
GSCO
10/06/16
NO CHANGE
Target $71
GSCO
Buy
AveXis attractive acquisition target, price target to $71 at Goldman
Goldman analyst Salveen Richter said AveXis has two approaching catalysts coming up, the AVXS-101 update in SMA Type 1 at the World Muscle Society, or WMS, on October 8, and clarity on the AVXS-101 pivotal trial design in late October/early November. The analyst expects positive WMS data and raaised his probability of success to 60% from 45%. He expects compelling motor milestone data and pivotal trial visibility to make AveXis an attractive acquisition target and raised his price target to $71 from $46 on shares and reiterated his Buy rating.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).

TODAY'S FREE FLY STORIES

RMP

Rice Midstream

$22.20

0.05 (0.23%)

, EQGP

EQT GP

$28.44

-0.19 (-0.66%)

05:24
01/22/18
01/22
05:24
01/22/18
05:24
Downgrade
Rice Midstream, EQT GP, EQT Corporation rating change  »

Rice Midstream resumed…

RMP

Rice Midstream

$22.20

0.05 (0.23%)

EQGP

EQT GP

$28.44

-0.19 (-0.66%)

EQT

EQT Corporation

$56.03

-1.12 (-1.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$68.56

-0.46 (-0.67%)

05:22
01/22/18
01/22
05:22
01/22/18
05:22
Periodicals
Woman falls to death from balcony aboard Carnival ship, Miami Herald reports »

A woman aboard the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQM

EQT Midstream Partners

$76.51

0.17 (0.22%)

, EQGP

EQT GP

$28.44

-0.19 (-0.66%)

05:21
01/22/18
01/22
05:21
01/22/18
05:21
Downgrade
EQT Midstream Partners, EQT GP, Rice Midstream rating change  »

EQT Midstream Partners…

EQM

EQT Midstream Partners

$76.51

0.17 (0.22%)

EQGP

EQT GP

$28.44

-0.19 (-0.66%)

RMP

Rice Midstream

$22.20

0.05 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQGP

EQT GP

$28.44

-0.19 (-0.66%)

05:19
01/22/18
01/22
05:19
01/22/18
05:19
Initiation
EQT GP initiated  »

EQT GP resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$56.03

-1.12 (-1.96%)

05:18
01/22/18
01/22
05:18
01/22/18
05:18
Initiation
EQT Corporation initiated  »

EQT Corporation resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANDX

Andeavor Logistics

$52.52

0.12 (0.23%)

05:16
01/22/18
01/22
05:16
01/22/18
05:16
Initiation
Andeavor Logistics initiated  »

Andeavor Logistics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

ANDV

Andeavor

$118.35

0.14 (0.12%)

05:15
01/22/18
01/22
05:15
01/22/18
05:15
Initiation
Andeavor initiated  »

Andeavor resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

IPAR

Inter Parfums

$47.80

0.9 (1.92%)

05:13
01/22/18
01/22
05:13
01/22/18
05:13
Downgrade
Inter Parfums rating change  »

Inter Parfums downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

X

U.S. Steel

$38.77

-0.26 (-0.67%)

, STLD

Steel Dynamics

$46.42

0.16 (0.35%)

05:11
01/22/18
01/22
05:11
01/22/18
05:11
Upgrade
U.S. Steel, Steel Dynamics, Nucor, Commercial Metals rating change  »

U.S. Steel upgraded to…

X

U.S. Steel

$38.77

-0.26 (-0.67%)

STLD

Steel Dynamics

$46.42

0.16 (0.35%)

NUE

Nucor

$68.72

-0.1 (-0.15%)

CMC

Commercial Metals

$24.82

-0.27 (-1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 30

    Jan

  • 01

    Feb

ESPR

Esperion

$77.20

2.24 (2.99%)

05:06
01/22/18
01/22
05:06
01/22/18
05:06
Downgrade
Esperion rating change  »

Esperion downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$21.52

-0.58 (-2.62%)

05:02
01/22/18
01/22
05:02
01/22/18
05:02
Recommendations
Valeant analyst commentary  »

Valeant selloff Friday…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 18

    Jun

  • 27

    Aug

WP

Worldpay

$78.73

-0.35 (-0.44%)

04:57
01/22/18
01/22
04:57
01/22/18
04:57
Recommendations
Worldpay analyst commentary  »

Worldpay price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QDEL

Quidel

$46.93

0.46 (0.99%)

, QGEN

Qiagen

$32.87

0.31 (0.95%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Recommendations
Quidel, Qiagen analyst commentary  »

Quidel price target…

QDEL

Quidel

$46.93

0.46 (0.99%)

QGEN

Qiagen

$32.87

0.31 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCO

Moody's

$159.18

1.6 (1.02%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Moody's management to meet with RBC Capital »

RBC Capital Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 09

    Feb

04:55
01/22/18
01/22
04:55
01/22/18
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

AKTX

Akari Therapeutics

$3.59

-0.01 (-0.28%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Akari Therapeutics management to meet with William Blair »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

SANM

Sanmina

$35.45

0.5 (1.43%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Sanmina to hold a conference call »

Management holds an…Webcast Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

JAGX

Jaguar Health

$0.16

-0.0169 (-9.83%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Jaguar Health to hold a conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

FE

FirstEnergy

$29.40

-0.16 (-0.54%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
FirstEnergy participates in a webcast with Wolfe Research »

Utilities Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

04:55
01/22/18
01/22
04:55
01/22/18
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
UBS REITs analyst holds an analyst/industry conference call »

REITs Analyst Yulico…

BNED

Barnes & Noble Education

$7.70

0.25 (3.36%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Barnes & Noble Education management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

LLEX

Lilis Energy

$4.99

-0.12 (-2.35%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Lilis Energy management to meet with Seaport Global »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 24

    Jan

  • 30

    Jan

  • 31

    Jan

NAVG

Navigators

$49.65

0.4 (0.81%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Navigators management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 16

    Feb

PETS

PetMed Express

$53.24

2.67 (5.28%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Technical Analysis
Technical Earnings Preview: PetMed Express at life highs before news »

The stock is at life…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.